ArticleHuman vaccines & immunotherapeutics2014
Outbreak of mumps in a school setting, United Kingdom, 2013.
Article in Human vaccines & immunotherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Epidemiological trends and determinants of mumps outbreaks: a systematic review and meta-analysis.Frontiers in public health · 2025Pooled it
- Incremental effectiveness of the second dose of mumps-containing vaccine among children 9 months to 6 years in Hefei: A matched case-control study.Human vaccines & immunotherapeutics · 2025Article
- Forecasting the Incidence of Mumps Based on the Baidu Index and Environmental Data in Yunnan, China: Deep Learning Model Study.Journal of medical Internet research · 2025Article
- Epidemiological Characteristics of Mumps Cases in the Kingdom of Bahrain From 2012 to 2022.Cureus · 2024Article
- Modeling the population-level impact of a third dose of MMR vaccine on a mumps outbreak at the University of Iowa.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Effectiveness and safety of a mumps containing vaccine in preventing laboratory-confirmed mumps cases from 2002 to 2017: A meta-analysis.Open life sciences · 2024Article
- Mumps-specific antibody persistence in children aged 3-7 years immunized with two doses of mumps-containing vaccines: A prospective cohort study in Jiangsu Province, China.Human vaccines & immunotherapeutics · 2023Article
- Improved Immunogenicity of the Inactivated F Genotype Mumps Vaccine against Diverse Circulating Mumps Viruses in Mice.Vaccines · 2023Article
- Epidemiological characteristics of mumps from 2004 to 2020 in Jiangsu, China: a flexible spatial and spatiotemporal analysis.Epidemiology and infection · 2022Article
- An Economic Analysis of Mumps Vaccination in Fiji: Static Model Simulation of Routine Measles-Mumps-Rubella (MMR) Vaccination Instead of Current Measles-Rubella (MR) Vaccination.International journal of environmental research and public health · 2022Article
- The incidence of mumps in Taiwan and its association with the meteorological parameters: An observational study.Medicine · 2021Observational
- Mumps: an Update on Outbreaks, Vaccine Efficacy, and Genomic Diversity.Clinical microbiology reviews · 2020Review
- Current Status of Mumps Virus Infection: Epidemiology, Pathogenesis, and Vaccine.International journal of environmental research and public health · 2020Review
- The role of meteorological factors on mumps incidence among children in Guangzhou, Southern China.PloS one · 2020Article
- Epidemiological Characteristics and Spatiotemporal Analysis of Mumps from 2004 to 2018 in Chongqing, China.International journal of environmental research and public health · 2019Article
- Should Mumps Be Higher Up on the Public Health Agenda in India? A Concern for Global Health Security.Medical sciences (Basel, Switzerland) · 2018Article
- Review
- Recommendation of the Advisory Committee on Immunization Practices for Use of a Third Dose of Mumps Virus-Containing Vaccine in Persons at Increased Risk for Mumps During an Outbreak.MMWR. Morbidity and mortality weekly report · 2018Article
- Mumps Virus Nucleoprotein and Hemagglutinin-Specific Antibody Response Following a Third Dose of Measles Mumps Rubella Vaccine.Open forum infectious diseases · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effective protection against mumps can be achieved through 2 doses of the measles-mumps-rubella (MMR) vaccine. However, outbreaks of mumps have recently been described among populations with high vaccination coverage, including 2 doses of MMR. Here we describe an outbreak at a school in the East of England, UK. The school was attended by 540 pupils aged 10-19 years and had 170 staff. In total, 28 cases of mumps (24 pupils and 4 staff) were identified during 10 January to 16 March 2013. Vaccination status was known in 25 of the cases, and among these 21 (84.0%) had a documented history of 2 doses of MMR while the remaining had a history of one dose (2/25 cases, 8.0%) or no doses (2/25, 8.0%) of MMR. An outbreak control team recommended that MMR vaccine should be offered to all pupils whose parents consented to it, regardless of previous vaccination status. Additional MMR vaccines were administered to 103 pupils, including 76 (73.8%) third doses of MMR. Offering an additional dose of MMR appeared to be acceptable to parents, and we found it feasible to administer the intervention in a timely manner with resources from the local Public Health Centre (Primary Care Trust). An additional dose of MMR to all individuals at risk can be considered as an acceptable control measure for mumps outbreaks in schools even if the vaccination coverage is high. However, further evidence on the effectiveness, acceptability, and safety of this intervention is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.